Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
MWN-AI** Summary
Grace Therapeutics, Inc. (Nasdaq: GRCE), a late-stage biopharmaceutical company based in Princeton, N.J., is gearing up to participate in the TD Cowen 46th Annual Health Care Conference from March 2 to 4, 2026, in Boston, MA. Chief Executive Officer Prashant Kohli is scheduled to present on March 4 at 10:30 AM Eastern Time. His presentation will highlight the company's advanced clinical-stage asset, GTx-104, a novel injectable formulation of nimodipine, designed for IV infusion to treat aneurysmal subarachnoid hemorrhage (aSAH), a condition associated with high unmet medical needs.
Aneurysmal subarachnoid hemorrhage occurs when an aneurysm ruptures, causing bleeding between the brain and skull, and accounts for approximately 5% of all strokes in the U.S., impacting roughly 42,500 hospitalized patients annually. GTx-104 employs innovative nanoparticle technology to create a water-soluble form of nimodipine, facilitating IV delivery. This method streamlines administration, particularly in patients who are unconscious or have difficulty swallowing, and may mitigate issues related to oral dosing, such as food interactions and dosing errors.
The drug has been safely administered to over 200 participants, demonstrating a favorable pharmacokinetic profile compared to traditional oral nimodipine. Grace Therapeutics focuses on rare and orphan diseases, and its commitment is underscored by the Orphan Drug Designation received for GTx-104, which ensures marketing exclusivity in the U.S. after approval. With more than 40 patents granted or pending, the company is positioned to improve patient outcomes and advance therapeutic options within the biopharmaceutical landscape.
For additional details or to register for the conference webcast, interested parties can visit Grace Therapeutics’ official website.
MWN-AI** Analysis
Investors should keenly watch Grace Therapeutics (Nasdaq: GRCE) as it prepares for its presentation at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The focus on GTx-104, a novel injectable formulation of nimodipine, highlights the company’s strategic commitment to addressing significant unmet medical needs among patients suffering from aneurysmal subarachnoid hemorrhage (aSAH).
With the prevalence of aSAH in hospital-treated patients and the current lack of effective treatment options, GTx-104 has the potential to capture a substantial market share. Its unique nanoparticle technology enables standard IV infusion, which is particularly advantageous for unconscious or dysphagic patients, reducing reliance on nasogastric tubes. This innovative drug delivery method may ease concerns surrounding food interactions and dosing errors, positioning GTx-104 as a safer, more efficient alternative to the oral version of nimodipine.
As the company has already administered GTx-104 to over 200 individuals, its favorable safety profile and reduced pharmacokinetic variability suggest a promising efficacy profile. This could significantly elevate investor confidence, especially given that each of Grace Therapeutics’ lead clinical assets holds Orphan Drug Designation, a distinction that could provide considerable market exclusivity if the drugs receive FDA approval.
The upcoming conference provides a critical platform for CEO Prashant Kohli to articulate the strategic vision and potential of GTx-104 to investors, which may catalyze renewed interest and investment in the company. As the market increasingly favors companies advancing innovative therapies for rare diseases, those considering a position in Grace Therapeutics should stay informed on the outcomes of this conference and subsequent clinical trial developments, keeping in mind the potential for significant upside.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen’s 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA.
Mr. Kohli’s presentation is schedule for March 4, 2026 at 10:30 AM Eastern Time. To register for the webcast, click here. An archived replay will be available for 90 days following the event.
In addition, Mr. Kohli will participate in one-on-one and group investor meetings.
About aneurysmal Subarachnoid Hemorrhage (aSAH)
aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is a relatively uncommon type of stroke (aSAH) that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients.
About GTx-104
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine.
About Grace Therapeutics
Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.
For more information, please visit: www.gracetx.com.
For more information, please contact:
Grace Therapeutics Contact:
Prashant Kohli
Chief Executive Officer
Tel: 609-322-1602
Email: info@gracetx.com
www.gracetx.com
Investor Relations:
LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: mmoyer@lifesciadvisors.com
FAQ**
How does Grace Therapeutics Inc. (GRCE) plan to leverage its late-stage GTx-104 to address the challenges faced by aSAH patients during the upcoming TD Cowen's Health Care Conference?
Can Grace Therapeutics Inc. (GRCE) provide insights into the patient feedback and clinical outcomes observed from the over 200 patients administered GTx-104?
In what ways does Grace Therapeutics Inc. (GRCE) anticipate that the unique nanoparticle technology of GTx-104 will improve treatment efficacy for aSAH compared to standard nimodipine administration?
What strategies does Grace Therapeutics Inc. (GRCE) intend to implement post-approval to maximize the potential benefits of the FDA's Orphan Drug Designation for GTx-104?
**MWN-AI FAQ is based on asking OpenAI questions about Grace Therapeutics Inc. (NASDAQ: GRCE).
NASDAQ: GRCE
GRCE Trading
-5.15% G/L:
$2.32 Last:
105,312 Volume:
$2.38 Open:
